Austrianova and the Research Institute of Virology & Biomedicine granted retroviral patent in Europe
Austrianova announced that its primary academic partner, The Research Institute of virology and Biomedicine at the Veterinary University of medicine, has been granted a patent from the European patent office. The proprietary technology relates to a new kind of retroviral vector known as ReCon (reconstituting vector).
"We are extremely pleased that this technology has been deemed both novel and inventive" said Prof. Walter H. Günzburg, Head of the Research Institute and a co-inventor. ReCon allows the production of retroviral vectors carrying toxic or cytostatic genes from vector producing cells and thus circumvents a common problem encountered when using previous generations of retroviral vector.
The exclusive licensee of this technology is the Research Institute's partner, Austrianova. "We can apply these innovative vectors for the treatment of solid tumours in combination with therapeutic genes that can directly kill cancer cells" commented Brian Salmons, Managing Partner: Science and Technology, Austrianova.
Other news from the department research and development
